COVID-19 causes a wide spectrum of clinical manifestations, ranging from silent or mild symptoms to hypoxic pneumonia and multi-organ failure. At the start of the pandemic, it was unclear why some individuals were more vulnerable than others to this disease. However, recent discoveries have revealed that the presence of autoantibodies against immune-modulating proteins in some individuals hampers their ability to mount an effective immune response against SARS-CoV-2 and other viruses. Information is key, and our ability to detect these autoantibodies is crucial to prevent severe disease in the future.
Mirimus is developing an advanced immunoassay to identify individuals susceptible to life-threatening infections. Our groundbreaking technology focuses on the detection of anti-IFN autoantibodies, which have a strong correlation with life-threatening infections and unfavorable outcomes. By identifying these autoantibodies, our immunoassay will enable the early identification of individuals at risk, allowing for close monitoring and prompt medical intervention upon infection. This proactive approach will play a pivotal role in preventing poor outcomes, saving lives, and alleviating the burden on healthcare systems.
The immune system protects us from disease and infection. If the immune system malfunctions, it may mistakenly attack healthy cells, leading to inflammation, tissue damage, and dysfunction. Complications include end organ failure and potentially life-threatening conditions
Mirimus has developed an advanced computational, machine-learning algorithm to predict proteins that might be neutralized by pathogenic autoantibodies. We are now in the process of performing experimental validation of select targets with the goal of building a panel of advanced diagnostic immunoassays. Our goal is to improve patient outcomes through early and accurate detection, personalized treatment approaches, and a deeper understanding of the underlying mechanisms.
Through our research, we strive to improve the understanding and management of autoimmune diseases, ultimately empowering both patients and healthcare providers with the knowledge and tools necessary to navigate these conditions with confidence.
